journal
https://read.qxmd.com/read/38703389/cumulative-tenofovir-exposure-among-patients-with-human-immunodeficiency-virus-hepatitis-b-co-infection-with-differential-viral-suppression
#1
JOURNAL ARTICLE
Helen L Zhang, Meredith Mock, Lane Bushman, Peter L Anderson, Jennifer J Kiser, Susanna Naggie
This case-control study explored cumulative tenofovir exposure among patients with HIV/HBV co-infection with HIV viral suppression. Among patients taking tenofovir disoproxil fumarate, median TFV-DP levels in dried blood spots were ∼3-fold lower among patients with incomplete HBV viral suppression (n=4) compared to those with complete suppression (n=5) (516 vs.1456 fmol/punch).
May 3, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38703388/cabotegravir-and-rilpivirine-long-acting-injectables-in-a-pregnant-woman-living-with-hiv
#2
JOURNAL ARTICLE
Lena van der Wekken-Pas, Fabian Weiss, Charlotte Simon-Zuber, Rena Sebisch, Carmen Wiese, Elisabeth van Leeuwen, David Burger, Angela Colbers
This case report describes bimonthly LAI CAB/RPV prior to and throughout pregnancy. CAB concentration was comparable to non-pregnant individuals, RPV was 70-75% lower. No virologic failure orvertical transmission occurred. Despite placental transfer, no congenital malformations were noted. Bimonthly CAB/RPV LAI may not be suitable for pregnant women and monitoring of exposed infants is warranted.
May 3, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38700036/the-effect-of-covid-19-vaccination-on-outpatient-antibiotic-prescribing-in-older-adults-a-self-controlled-risk-interval-study
#3
JOURNAL ARTICLE
Sarah C J Jorgensen, Kevin Brown, Anna E Clarke, Kevin L Schwartz, Colleen Maxwell, Nick Daneman, Jeffrey C Kwong, Derek R MacFadden
BACKGROUND: Coronavirus disease 2019 (COVID-19) vaccination has been associated with reduced outpatient antibiotic prescribing among older adults with laboratory-confirmed severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). We assessed the impact of COVID-19 vaccination on outpatient antibiotic prescribing in the broader population of older adults, regardless of SARS-CoV-2 infection status. METHODS: We included adults aged ≥65 years who received their first, second, and/or third COVID-19 vaccine dose from December 2020 to December 2022...
May 3, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38699997/correspondence-on-the-validation-of-the-duke-iscvid-criteria-for-the-diagnosis-of-infective-endocarditis-what-of-the-new-major-microbiological-criteria
#4
JOURNAL ARTICLE
Cristiane Lamas
No abstract text is available yet for this article.
May 3, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38699994/duke-iscvid-criteria-in-patients-with-negative-blood-cultures
#5
JOURNAL ARTICLE
Thomas W van der Vaart, Vance G Fowler, Jan T M van der Meer
No abstract text is available yet for this article.
May 3, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38690892/favorable-antiviral-effect-of-metformin-on-severe-acute-respiratory-syndrome-coronavirus-2-viral-load-in-a-randomized-placebo-controlled-clinical-trial-of-coronavirus-disease-2019
#6
JOURNAL ARTICLE
Carolyn T Bramante, Kenneth B Beckman, Tanvi Mehta, Amy B Karger, David J Odde, Christopher J Tignanelli, John B Buse, Darrell M Johnson, Ray H B Watson, Jerry J Daniel, David M Liebovitz, Jacinda M Nicklas, Ken Cohen, Michael A Puskarich, Hrishikesh K Belani, Lianne K Siegel, Nichole R Klatt, Blake Anderson, Katrina M Hartman, Via Rao, Aubrey A Hagen, Barkha Patel, Sarah L Fenno, Nandini Avula, Neha V Reddy, Spencer M Erickson, Regina D Fricton, Samuel Lee, Gwendolyn Griffiths, Matthew F Pullen, Jennifer L Thompson, Nancy E Sherwood, Thomas A Murray, Michael R Rose, David R Boulware, Jared D Huling
BACKGROUND: Metformin has antiviral activity against RNA viruses including severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). The mechanism appears to be suppression of protein translation via targeting the host mechanistic target of rapamycin pathway. In the COVID-OUT randomized trial for outpatient coronavirus disease 2019 (COVID-19), metformin reduced the odds of hospitalizations/death through 28 days by 58%, of emergency department visits/hospitalizations/death through 14 days by 42%, and of long COVID through 10 months by 42%...
May 1, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38690870/repurposing-revisited-exploring-the-role-of-metformin-for-treatment-of-coronavirus-disease-2019
#7
JOURNAL ARTICLE
Mark J Siedner, Paul E Sax
No abstract text is available yet for this article.
May 1, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38687895/correction-to-impact-of-seasonal-coronavirus-antibodies-on-severe-acute-respiratory-syndrome-coronavirus-2-vaccine-responses-in-solid-organ-transplant-recipients
#8
(no author information available yet)
No abstract text is available yet for this article.
April 30, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38687891/correction-to-targeting-tularemia-clinical-laboratory-and-treatment-outcomes-from-an-11-year-retrospective-observational-cohort-in-northern-sweden
#9
(no author information available yet)
No abstract text is available yet for this article.
April 30, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38687590/correction-to-safety-tolerability-and-pharmacokinetics-of-jnj-1802-a-pan-serotype-dengue-direct-antiviral-small-molecule-in-a-phase-1-double-blind-randomized-dose-escalation-study-in-healthy-volunteers
#10
https://read.qxmd.com/read/38687584/correction-to-differential-cytokine-signatures-of-severe-acute-respiratory-syndrome-coronavirus-2-sars-cov-2-and-influenza-infection-highlight-key-differences-in-pathobiology
#11
(no author information available yet)
No abstract text is available yet for this article.
April 30, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38676943/rapid-diagnostic-tests-and-antimicrobial-stewardship-programs-for-the-management-of-bloodstream-infection-what-is-their-relative-contribution-to-improving-clinical-outcomes-a-systematic-review-and-network-meta-analysis
#12
JOURNAL ARTICLE
Anna Maria Peri, Mark D Chatfield, Weiping Ling, Luis Furuya-Kanamori, Patrick N A Harris, David L Paterson
BACKGROUND: Evidence about the clinical impact of rapid diagnostic tests (RDT) for the diagnosis of bloodstream infections is limited, and whether RDT are superior to conventional blood cultures (BC) embedded within antimicrobial stewardship programs (ASP) is unknown. METHODS: We performed network meta-analyses (NMA) using results from studies of patients with bloodstream infection with the aim of comparing the clinical impact of RDT (applied on positive BC broth or whole blood) to conventional BC, both assessed with and without ASP with respect to mortality, length of stay (LOS) and time to optimal therapy (TOT)...
April 27, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38669212/correction-to-antibiotic-myths-for-the-infectious-diseases-clinician
#13
(no author information available yet)
No abstract text is available yet for this article.
April 26, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38666501/the-impact-of-pre-transplant-respiratory-virus-detection-on-post-transplant-outcomes-in-children-undergoing-hematopoietic-cell-transplantation
#14
JOURNAL ARTICLE
Sara Ruth Kim, Anna Nordlander, Hu Xie, Yae-Jean Kim, Chikara Ogimi, Monica S Thakar, Wendy Leisenring, Janet A Englund, Michael Boeckh, Alpana Waghmare
BACKGROUND: Pre-transplant respiratory virus (RV) infections have been associated with negative transplant outcomes in adult hematopoietic cell transplantation (HCT) recipients. In the era of HCT delay due to high-risk RVs, we examined the impact of pre-transplant RV detection on transplant outcomes in a pediatric HCT recipients. METHODS: This retrospective cohort study included myeloablative allogeneic HCT recipients from 2010 to 2019. All patients were screened for RV at least once within 90 days before HCT using RT-PCR, regardless of symptoms...
April 26, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38666472/origin-of-antimicrobial-therapy
#15
JOURNAL ARTICLE
Powel Kazanjian
Medical historians typically situate the origins of the antimicrobial era during the early germ period at the turn of the 20th century. They have regarded the development of chemical compounds designed to treat infectious diseases by killing their causative germ as the beginning of the antimicrobial era. Scholars, however, had been speculating about the causal relationship between germs and diseases for centuries beforehand. One of them also addressed the practical applications of this theory. The Italian physician Fracastoro proposed in 1546 that infectious diseases could be treated by administering substances to antagonize disease causing germs...
April 26, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38666412/performance-of-urinalysis-parameters-in-predicting-urinary-tract-infection-does-one-size-fit-all
#16
JOURNAL ARTICLE
Sonali D Advani, Rebecca North, Nicholas A Turner, Sahra Ahmadi, Julia Denniss, Adero Francis, Rachel Johnson, Anum Hasan, Faryal Mirza, Sarah Pardue, Meghana Rao, Yasmin Rosshandler, Helen Tang, Kenneth E Schmader, Deverick J Anderson
In a multi-hospital cohort study of 3392 patients, positive urinalysis parameters had poor positive predictive value for diagnosing urinary tract infection (UTI). Combined urinalysis parameters (pyuria or nitrite) performed better than pyuria alone for ruling out UTI. However, performance of all urinalysis parameters was poor in older women.
April 26, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38666408/bictegravir-use-during-pregnancy-a-multi-center-retrospective-analysis-evaluating-hiv-viral-suppression-and-perinatal-outcomes
#17
JOURNAL ARTICLE
Lauren M Holt, William R Short, Florence Momplaisir, Eleanor Hyun, Jennifer McKinney, Andrea Lugo Morales, Alejandra Duque, Brian Druyan, Chima Ndubizu, Luthita Duthely, Naima Joseph, Anandi Sheth, Martina L Badell
This study describes the largest cohort to date (n=147) of pregnant patients living with HIV on bictegravir (BIC). BIC in pregnancy was associated with high levels of viral suppression and similar perinatal outcomes to published literature. These findings support consideration for use of BIC in management of HIV during pregnancy.
April 26, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38663013/trends-in-mortality-in-people-with-hiv-from-1999-to-2020-a-multi-cohort-collaboration
#18
JOURNAL ARTICLE
Erich Tusch, Lene Ryom, Annegret Pelchen-Matthews, Amanda Mocroft, Daniel Elbirt, Cristiana Oprea, Huldrych F Günthard, Cornelia Staehelin, Robert Zangerle, Isabelle Suarez, Jörg Janne Vehreschild, Ferdinand Wit, Marianna Menozzi, Antonella d'Arminio Monforte, Vincenzo Spagnuolo, Christian Pradier, Christina Carlander, Paula Suanzes, Jan-Christian Wasmuth, Andrew Carr, Kathy Petoumenos, Frauke Borgans, Fabrice Bonnet, Stephane De Wit, Wafaa El-Sadr, Bastian Neesgaard, Nadine Jaschinski, Lauren Greenberg, Sean R Hosein, Joel Gallant, Vani Vannappagari, Lital Young, Caroline Sabin, Jens Lundgren, Lars Peters, Joanne Reekie
BACKGROUND: Mortality among people with HIV declined with the introduction of combination antiretroviral therapy. We investigated trends over time in all-cause and cause-specific mortality in people with HIV from 1999-2020. METHODS: Data were collected from the D:A:D cohort from 1999 through January 2015 and RESPOND from October 2017 through 2020. Age-standardized all-cause and cause-specific mortality rates, classified using Coding Causes of Death in HIV (CoDe), were calculated...
April 26, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38661186/the-growing-threat-of-ndm-producing-e-coli-with-penicillin-binding-protein-3-mutations-in-the-united-states-is-there-a-potential-role-for-durlobactam
#19
JOURNAL ARTICLE
Samuel L Aitken, Virginia M Pierce, Jason M Pogue, Ellen G Kline, Frank P Tverdek, Ryan K Shields
We report identification of 5 patients with infections caused by NDM-5-producing E. coli harboring PBP3 mutations that showed reduced susceptibility to aztreonam-avibactam and cefiderocol. Durlobactam, a novel diazabicyclooctane β-lactamase inhibitor, demonstrated minimum inhibitory concentrations ranging from 0.5 to 2 µg/mL supporting future investigations into a potential role in clinical management.
April 25, 2024: Clinical Infectious Diseases
https://read.qxmd.com/read/38658348/a-novel-risk-adjusted-metric-to-compare-hospitals-on-their-antibiotic-prescribing-at-hospital-discharge
#20
JOURNAL ARTICLE
Daniel J Livorsi, James A Merchant, Hyunkeun Cho, Matthew Bidwell Goetz, Bruce Alexander, Brice Beck, Michihiko Goto
BACKGROUND: Antibiotic overuse at hospital discharge is common, but there is no metric to evaluate hospital performance at this transition of care. We built a risk-adjusted metric for comparing hospitals on their overall post-discharge antibiotic use. METHODS: This was a retrospective study across all acute-care admissions within the Veterans Health Administration during 2018-2021. For patients discharged to home, we collected data on antibiotics and relevant covariates...
April 24, 2024: Clinical Infectious Diseases
journal
journal
20074
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.